Intraoperative OCT Guidance of Intraocular Surgery (MIOCT)
The purpose of this study is to investigate the use of optical coherence tomography imaging integrated with an operating microscope (MIOCT) in ophthalmic surgeries.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Intraoperative OCT Guidance of Intraocular Surgery|
- Test and provide feedback on the intraoperative system both in laboratory and then in the operating room. [ Time Frame: 8.5 years ] [ Designated as safety issue: No ]The primary outcome of this project is to integrate optical coherence tomography (OCT) with the surgical environment through novel advances in OCT technology, automated tracking of surgical instruments and tools, and fusion of OCT controls, images and measurements into a seamless interface for the surgeon.
|Study Start Date:||September 2009|
|Estimated Study Completion Date:||January 2018|
|Estimated Primary Completion Date:||January 2018 (Final data collection date for primary outcome measure)|
Vitreoretinal Interface Disease Group
A minimum of 50 subjects with vitreoretinal interface disease will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
Macular Hole Group
A minimum of 50 subjects with macular hole with be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
Retinal Detachment Group
A minimum of 50 subjects with retinal detachment will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
Diabetic Retinopathy Group
A minimum of 50 subjects with diabetic retinopathy will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
Rare Related Macular Disease Group
Up to 70 subjects with rare related macular diseases will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
Generation 2 MIOCT Transition Group
80 of the subjects recruited in years 1 through 5 (40 normal, 40 diseased) will be imaged with both the generation 1 MIOCT and the generation 2 MIOCT systems prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
Endothelial Keratoplasty Group
150 subjects undergoing Descemet Stripping Endothelial Keratoplasty (DSEK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
Anterior Lamellar Keratoplasty Group
150 subjects undergoing Deep Anterior Lamellar Keratoplasty (DALK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
Optical Coherence Tomography (OCT) is used to capture reproducible ocular morphology and cross-sectional tissue measurements in-vivo in a rapid, non-invasive, non-contact manner. It has displaced ophthalmoscopy and stereo photography for clinical assessment and documentation of retinal microanatomy including thickness, cystoid structures, subretinal fluid and retinal traction.(1) Spectral Domain Optical Coherence Tomography (SDOCT) has the speed and resolution required for real-time noninvasive three-dimensional imaging of critical pathology.
While modern ophthalmic surgery has benefited from rapid advances in instrumentation and techniques (2-6), the basic principles of the stereo zoom operating microscope have not changed (except for increased automation) since the 1930's. (7-9) The ability to better resolve tissue microanatomy through real-time micro-imaging would have a dramatic impact on ophthalmic surgeon's capabilities, foster the development of new surgical techniques, and potentially improve surgical outcomes.
Complementary to microscope integrated OCT (MIOCT) testing, we use a commercial hand-held SDOCT instrument (Bioptigen, Inc.) during pauses in both anterior segment and retinal surgery to document surgical process.
While both the handheld instrument and Duke's Generation 1 (G1) MIOCT prototype have demonstrated that high-quality OCT imaging is possible during surgery, in both cases control of the OCT scan location and display of the real-time image data are managed on the OCT system console, located up to several feet from the surgeon. Thus, the potential dramatic impact of this technology on ophthalmic surgery is constrained by its limited integration with the surgical environment. The primary technical goal of this project is to address this issue through novel advances in OCT technology, automated tracking of surgical instruments and tools, and fusion of OCT controls, images and measurements into a seamless interface for the surgeon.
This study will facilitate future quality improvement processes based on intraoperative data matched to postoperative outcomes. Intraoperative OCT feedback will revolutionize communication in surgical research, clinical communication, surgeon training and continuing education, and will provide measurable data regarding disease patterns and intraoperative response, novel instrument and adjuvant use.
This study will prospectively examine the surgical utility of MIOCT in retinal and anterior segment surgery. A total of 722 subjects will be enrolled at 2 sites, Duke Eye Center and Cole Eye Institute. Of those, there will be 500 retina subjects and 222 anterior segment subjects. There will be a small number of normal subjects, who are not undergoing eye surgery, enrolled in this portion of this study for non-surgical study of the MIOCT system imaging, particularly for Generation 2 (G2) MIOCT. Rate of recruitment: 460 retina subjects will be enrolled at the rate of approximately 115 per year (~57 per year at both Duke and Cole) for years 1-4 and approximately 40 subjects will be enrolled in year 5 (adding up to a total of 500 subjects).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01588041
|Contact: Cynthia A Toth, MDemail@example.com|
|Contact: Michelle N McCall, MCAPM, BAfirstname.lastname@example.org|
|United States, North Carolina|
|Duke University Eye Center||Recruiting|
|Durham, North Carolina, United States, 27705|
|Contact: Cynthia A Toth, MD 919-684-5631 email@example.com|
|Contact: Michelle McCall, MCAPM, BA 919-684-0544 firstname.lastname@example.org|
|Principal Investigator: Cynthia A Toth, MD|
|Sub-Investigator: Paul S Hahn, MD, PhD|
|Sub-Investigator: Anthony Kuo, MD|
|United States, Ohio|
|Cole Eye Institute at the Cleveland Clinic Lemer College of Medicine||Not yet recruiting|
|Cleveland, Ohio, United States, 44195|
|Contact: Sunil Srivastava, MD 216-636-2286 email@example.com|
|Contact: Ehlers Justis, MD (216) 636-2286 firstname.lastname@example.org|
|Principal Investigator: Sunil K Srivastava, MD|
|Sub-Investigator: Justis P Ehlers, MD|
|Sub-Investigator: William J Dupps, Jr., MD, PhD|
|Principal Investigator:||Cynthia A Toth, MD||Duke University Health System, Department of Ophthalmology|
|Principal Investigator:||Joseph A Izatt, PhD||Duke University Department of Biomedical Engineering|